Skip to main content
. Author manuscript; available in PMC: 2021 Jan 1.
Published in final edited form as: Mol Cancer Res. 2020 Apr 3;18(7):1018–1027. doi: 10.1158/1541-7786.MCR-19-1082

Figure 1.

Figure 1.

NFκB pathway is active in patients treated with neo-adjuvant tamoxifen therapy. A, Setup of a neo-adjuvant trial in which patients with small ER+ breast tumors received tamoxifen for several weeks. Pre-treatment biopsies were compared to surgical specimens taken several weeks later. B, Top five enriched gene sets (FDR q-value < 0.05) following tamoxifen treatment when comparing surgical specimens to pre-treatment biopsies. C, GSEA enrichment plot of the ‘TNFα signaling via NFκB’ geneset. D, Heatmap of genes in the ‘TNFα signaling via NFκB’ geneset that were found to be significantly differentially expressed when comparing surgical specimens to pre-treatment biopsies.